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Abstract: Urticaria and angioedema are common clinical con-
ditions representing a major concern for physicians and patients
alike. The World Allergy Organization (WAO), recognizing the
importance of these diseases, has contributed to previous guide-
lines for the diagnosis and management of urticaria. The Scientiﬁc
and Clinical Issues Council of WAO proposed the development of
this global Position Paper to further enhance the clinical manage-
ment of these disorders through the participation of renowned
experts from all WAO regions of the world. Sections on deﬁnition
and classiﬁcation, prevalence, etiology and pathogenesis, diagno-
sis, treatment, and prognosis are based on the best scientiﬁc
evidence presently available. Additional sections devoted to
urticaria and angioedema in children and pregnant women, quality
of life and patient-reported outcomes, and physical urticarias have
been incorporated into this document. It is expected that this article
will supplement recent international guidelines with the contribu-
tion of an expert panel designated by the WAO, increasing
awareness of the importance of urticaria and angioedema in
medical practice and will become a useful source of information
for optimum patient management worldwide.
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INTRODUCTION
Urticaria is a highly prevalent condition resulting in
large numbers of medical consultations worldwide. Its preva-
lence ranges between 0.3 and 11.3% depending on the study
population (see Prevalence section), and in recent years, an
increase in the rate of hospitalizations due to urticaria and angioe-
dema has been observed in some countries.1 It has been estimated
that approximately 20% of the population will experience an
episode of acute urticaria (AU) at some point in their lifetime.
Although urticaria has a tremendous impact on patient’s
quality of life, it is often disregarded as a trivial disease by
many physicians.2 Therefore, patients are not adequately edu-
cated on the nature of their condition and its proper manage-
ment, which involves not only pharmacological treatment but
also the implementation of preventive measures to reduce the
effects of various precipitating and aggravating factors.
This position paper provides updates on recent advan-
ces in the understanding of etiologic factors, pathogenic
mechanisms, diagnostic methods, and medical management
of acute and chronic urticaria (CU) and angioedema.
WORLD ALLERGY ORGANIZATION GLOBAL
POSITION PAPERS
The World Allergy Organization (WAO) is an interna-
tional federation of 89 regional and national allergy and
clinical immunology societies dedicated to raising awareness
and advancing excellence in clinical care, research, education,
and training in allergy and clinical immunology. This WAO
position paper on the diagnosis and treatment of urticaria and
angioedema was developed as a document presenting a world-
wide perspective encompassing the participation and input of
leaders from all WAO regional member societies.
This position paper includes sections on the deﬁnition,
prevalence, classiﬁcation, mechanisms, diagnosis, treatment,
and prognosis of urticaria and angioedema. In addition, special
chapters dealing with particularly important issues have been
included to review physical urticarias, urticaria in childhood,
urticaria and pregnancy, and quality of life and patient-
reported outcomes (PROs). The concept of disease control
for CU, similar to other chronic allergic diseases such as
asthma and rhinitis, is highlighted and the importance of
patient education on the possible mechanisms, causes, prog-
nosis, and treatment of acute and CU is emphasized.
National and regional guidelines for the diagnosis and
treatment of urticaria and angioedema have been previously
published.3–5 Because urticaria and angioedema are a frequent
cause for consultation not only in allergology clinics but also in
general practitioners’ ofﬁces, and these diseases are often under-
estimated by physicians, it was important to provide useful
orientations for the management of these vexing conditions.
The objectives of this WAO position paper on urticaria
and angioedema are to provide updated information on the
assessment and treatment that should be applied in health care
settings worldwide to obtain a better symptom control, improve
patients’ quality of life, contribute to patient education, and
enhance accessibility to more effective therapies. This informa-
tion is designed for use by both allergy and immunology spe-
cialists as well as physicians in general practices who daily
observe patients with urticaria and angioedema.
METHODS
This position paper was developed by a special steering
committee of internationally recognized experts appointed by
the WAO Scientiﬁc and Clinical Issues Council.
Recommendations are based on the best evidence pres-
ently available. Urticaria and angioedema guidelines previously
published in indexed peer-reviewed journals were reviewed.
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Drafts were developed through e-mail correspondence among
authors, distributed to all members of WAO Board of Directors
for comment, and then circulated to WAOMember Societies for
review, comments, and approval. In all, more than 50 allergy
and immunology specialists on 5 continents contributed to the
development of this position paper.
DEFINITION AND CLASSIFICATION
Urticaria is characterized by the sudden appearance of
wheals and/or angioedema, deﬁning wheals as a cutaneous
swelling of variable size, almost invariably surrounded by
a reﬂex erythema, with associated itching or, sometimes,
a burning sensation, and of transient nature, with the skin
returning to its normal appearance in usually 1 to 24 hours.
Angioedema can be deﬁned as a sudden and pro-
nounced swelling of the deep dermis and subcutaneous tissue
or mucous membranes, with a painful rather than an itching
sensation and a slower resolution than for wheals that can
take up to 72 hours.4,6
Classification
Urticaria can be classiﬁed on the basis of its duration
and in the presence or absence of inducing factors (induced vs
spontaneous).
Duration
AU is characterized by the occurrence of hives and/or
angioedema for ,6 weeks, whereas episodes lasting longer
than 6 weeks are regarded as CU.7 This somewhat arbitrary
distinction of 6 weeks becomes important in regard to poten-
tial mechanisms, approaches to evaluation, and options
for treatment. The classiﬁcation of urticaria is presented in
Table 1.
Urticaria pigmentosa (cutaneous mastocytosis), urticar-
ial vasculitis, familial cold urticaria, and nonhistaminergic
angioedema (eg, hereditary or acquired C1 esterase inhibitor
deﬁciency) are no longer considered as subtypes of urticaria,
due to their distinctly different pathomechanisms.4
Finally, there are syndromes that can be associated with
wheals:
• Muckle–Wells syndrome: a combination of wheals,
deafness, and amyloidosis, characterized by sensorineu-
ral deafness, recurrent urticaria, fever, and arthritis.8
• Schnitzler syndrome: chronic wheals and monoclonal
gammopathy (usually IgM) associated with at least 2 of
the following components: fever, arthralgia, or arthritis,
bone pain, hepatomegaly or splenomegaly or hepatosplee-
nomegaly, lymphadenopathy, elevated erythrocyte sedi-
mentation rate, leukocytosis, and/or abnormal ﬁndings
on bone morphological investigations.9
• Gleich syndrome: episodic angioedema with eosinophilia.10
• Well syndrome or eosinophilic cellulitis: granulomatous
dermatitis with eosinophilia.11
PREVALENCE
The prevalence of urticaria and angioedema varies
according to the population under investigation. Lifetime
prevalence rates of 8.8% have been reported, with a 1.8% rate
for CU.12 Approximately 10 to 20% of the population will
experience an episode of AU at some point in their lifetime,
and 0.1% will develop chronic spontaneous urticaria.13
In a study carried out in Spain, the prevalence of
urticaria in the past 12 months was 0.8%, and the prevalence
of CU was 0.6%. Urticaria was present more often in female
patients among the 35 to 60 years age-group (mean age,
40 years). Duration of the disease was 1 to 5 years in 8.7% of
the patients and more than 5 years in 11.3%.14
Autoimmune disturbances are present in 40 to 45% of
patients with chronic spontaneous urticaria.15 Angioedema is
present in 40 to 50% of cases of chronic spontaneous urticaria,
TABLE 1. Classification of Urticaria Subtypes (Presenting With Wheals and/or Angioedema) Based on the Different Eliciting
Stimuli
Types Subtypes Deﬁnition
Spontaneous urticaria Acute spontaneous urticaria Spontaneous wheals and/or angioedema ,6 wk
Chronic spontaneous urticaria Spontaneous wheals and/or angioedema .6 wk
Urticarias induced by physical agents Cold contact urticaria Eliciting factor: cold objects/air/ﬂuids/wind
Delayed pressure urticaria Eliciting factor: vertical pressure (wheals arising
with a 3–12 h latency)
Heat contact urticaria Eliciting factor: localized heat
Solar urticaria Eliciting factor: UV and/or visible light
Urticaria factitia/dermographic urticaria Eliciting factor: mechanical shearing forces (wheals
arising after 1–5 min)
Vibratory urticaria/angioedema Eliciting factor: vibratory forces, e.g. pneumatic
hammer
Other inducible urticarias Aquagenic urticaria Eliciting factor: water
Cholinergic urticaria Elicitation by increase of body core temperature due
to physical exercises, spicy food
Contact urticaria Elicitation by contact with urticariogenic substance
Exercise-induced anaphylaxis/urticaria Eliciting factor: physical exercise
Modiﬁed with permission from Zuberbier et al.4 Copyright 2009 John Wiley & Sons.
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10% of patients experience only angioedema without hives and
40% exhibit wheals alone.6,13,16 Recently, an increase in the rate
of hospital admissions for angioedema (3.0% per year), and
urticaria (5.7% per year) has been observed in Australia.
Admissions for urticaria were 3 times higher in children aged
0 to 4 years. The greatest increase in hospitalizations for urticaria
was present in those aged 5 to 34 years (7.8% per year), and for
angioedema, it was higher in patients 65 years and older.1 It is
not known if this increase has occurred in other countries.
ETIOLOGY AND PATHOGENESIS
Symptoms of chronic spontaneous urticaria appear
seemingly spontaneously, that is, in most patients, there is
no identiﬁable exogenous stimulus for hive production.
In some patients, however, nonspeciﬁc exogenous triggers
for the development of wheals and/or angioedema, such
as exercise, environmental changes, and stress are present.
We now consider this group to be chronic “spontaneous”
urticaria4,17; thus, if an etiology is to be found, it is likely
to be endogenous, leading to the resultant cutaneous inﬂam-
mation that is expressed as a hive.
Psychosomatic Factors
For decades, theories regarding etiology would appear
and disappear, but none proved to be credible. In the 1950s
and 1960s, many considered chronic spontaneous urticaria to
be an anxiety disorder, and even now, there is some limited
data to suggest worsening of symptoms with anxiety. It is now
generally accepted that mental illnesses, such as depression
and anxiety, inﬂuence the quality of life of chronic sponta-
neous urticaria patients and those are important comorbidities
in such patients. However, it cannot be considered to be
a cause, and a clear distinction between less tolerance of
symptoms and actual worsening of skin inﬂammation has not
been made.
Type 1 Food Allergy
The relation between food allergy/pseudoallergy and
CU is controversial because some experts do not recom-
mend elimination diets for such condition, whereas others
have observed the improvement of symptoms by means of
pseudoallergen-free diets in about one third of patients with
chronic spontaneous urticaria.18
Autoreactivity and Autoimmunity
Autoreactivity (see below) represents one major approach
to elucidating the initiating stimulus for persisting hive forma-
tion. It is clear that cutaneous mast cell degranulation induces
hive formation and on biopsy, a nonnecrotizing perivascular
inﬁltration of cells is seen, which resembles a cutaneous late
phase reaction.19–21 There is inﬁltration with granulocytes (neu-
trophils, eosinophils, and basophils), although the magnitude
can vary considerably. T cells are very prominent; most are
CD41 with a mixture of TH1 and TH2 subtypes.21 There are
also monocytes, but very few, if any B lymphocytes. A similar
inﬁltration of cells can be seen when serum of patients is
injected intradermally into their own skin, with a resultant wheal
and ﬂare reaction termed autoreactivity.22 This is seen in 30% of
patients and led to considerations of autoimmune (ie, immuno-
globulin) mechanisms for the initiation of mast cell degranula-
tion. At ﬁrst, 5 to 10% of patients were found to have circulating
IgG anti-IgE, which is functional,23 and subsequently, 30 to
40% of patients were found to have IgG antibody to the a
subunit of the IgE receptor.24 The thesis is that cross-linking
IgE receptors or occasionally IgE itself could activate skin mast
cells in a selective fashion. Most commonly, human basophils
were employed as an alternative to cutaneous mast cells and
worked well to identify what has been termed chronic autoim-
mune urticaria. Serum-evoked basophil histamine release (HR),
although time consuming, is the most quantitative assay, but
upregulation of CD63 or CD203 assessed by ﬂuorescence-acti-
vated cell sorter analysis can also be employed.
The remaining 55 to 60% of patients lacking such
autoimmunity are considered to have chronic nonautoimmune
or idiopathic (but nevertheless spontaneous) urticaria. In vitro
studies support antireceptor antibody binding to the a subunit
of the IgE receptor to activate the classical complement path-
way with release of C5a, which further activates basophils
and mast cells and contributes to recruitment of granulocytes
and monocytes by its chemotactic activity.25 Marked reduc-
tion in serum complement levels or complement deposition in
lesion biopsies have not been demonstrated in subjects with
serum autoimmunity.
The presence of these antibodies does not prove
causality, although their role as a pathogenic mechanism is
debated with evidence pro and con.26,27 Clearly, more than
half of the patient population with chronic spontaneous urti-
caria lacks these anti-FceRI autoantibodies. However, in vitro
HR can be blocked completely by saturating IgE receptors
with an IgE myeloma protein so that antireceptor antibodies
are sterically prevented from binding,28 although an occa-
sional exception is noted.29 Soluble a subunit can be added
to serum to bind the antireceptor antibody so that HR is
prevented.24,30 In most cases studied, isolation of IgG has
reproduced basophil activation based on HR, although the
IgG depleted serum is negative.
There are also publications suggesting the presence of
vasoactive factors in IgG-depleted serum of patients with
CU,31 but no factor has been isolated or identiﬁed, and the
assay employed for detection is more typically the autologous
skin test rather than basophil HR. Plasmapheresis can be used
to stop the urticaria acutely indicating that removal of a critical
plasma factor can potentially stop symptoms in select cases.32
Possible Role of Immunoglobulin E
Finally, it was theorized that anti-IgE therapy with
omalizumab might be effective in patients with hives. The
thesis was that as IgE levels decrease toward zero, IgE
receptors are downregulated, and if the spacing and surface
density is sufﬁciently low, the IgG anti-a subunit cannot
cross-link receptors and activation of basophil and mast cell
would not occur. In practice, the IgE receptor reduction via
omalizumab occurs rapidly for blood basophils and much more
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slowly on skin mast cells, yet omalizumab does not eliminate
either cell’s capacity to respond to a cross-linking stimulus.33–35
Thus far, therapy with this monoclonal antibody has been
extremely successful,36–38 and phase 3 studies of its efﬁcacy
and safety are ongoing currently. The mechanism of its effect is
not clear because some patients respond dramatically in 2 to 3
days; so fast that receptors could not be signiﬁcantly down-
regulated, and there is evidence of efﬁcacy even in the non-
autoimmune urticaria population.39,40 Thus, it is likely that
some unknown role for IgE is operative in all these patients,
whereas receptor downregulation is superimposed some weeks
later. There is precedent for synthesis of IgE that is either
intrinsically abnormal or perhaps reactive with an unknown
autoantigen; for example, it has been shown that isolated mono-
meric IgE of some patients with cold urticaria can passively
transfer the disease,41 that is, the IgE binds to normal mast cells
of a recipient and renders them “cold sensitive” so that mast
cells then degranulate upon a change in temperature. The abnor-
mality resides with the IgE not the mast cell. There is also
evidence for heightened skin mast cell release in active CU
subjects42–44; furthermore, a recent publication reports the pres-
ence of a nonimmunoglobulin factor in patient’s sera capable of
activating cultured mast cells in vitro.45
Additional Observations on the Pathogenesis
of Urticaria
There are additional observations regarding chronic
spontaneous urticaria possibly related to pathogenesis. Early
on, an association with Hashimoto thyroiditis, and more
speciﬁcally, with the presence of autoantibodies was
reported,46,47 including antiperoxidase and antithyroglobulin
antibodies. Although IgE antithyroid antibodies could have
pathogenic signiﬁcance, most patients have only IgG antibod-
ies, and their presence is thought to represent a proclivity to
autoimmune phenomena and a possible marker for the pres-
ence of anti-IgE receptor antibody.48 C-reactive protein is ele-
vated in the group when compared with normals, suggesting
systemic recognition of cutaneous inﬂammation. Matrix metal-
loproteinase levels are increased in the blood plasma perhaps
originating from skin inﬂammation.49 The extrinsic coagula-
tion cascade is activated based on elevated prothrombin frag-
ments 1 and 2 and D-dimer levels but without any abnormal
coagulopathy.50,51 Tissue factor, although produced by acti-
vated endothelial cells (stimulated, for example, by histamine
or leukotriene C4), nevertheless seems to be secreted by eosi-
nophils within the tissue.52 It has been theorized that thrombin
might activate mast cells; however, active thrombin has not
been found; most demonstrations of thrombin-induced HR
have employed rodent mast cells, and it is not clear that the
thrombin dose needed is physiologic.53,54 Leukotriene C4,
cytokines, and growth factors have also been found to be
elevated in plasma of patients with CU, and cellular adhesion
molecules are upregulated.55–57 It is not clear whether these
inﬂammatory stigmata are produced by activated cells in blood
or these are found to having been produced in the skin.
Another approach to understanding chronic spontane-
ous urticaria, whether associated with autoantibodies, is to
focus on possible abnormalities within the cell, and the
basophil is a prime candidate. A hallmark of CU is the unique
relationship of disease activity to altered blood basophil
phenotypes.58 Since the 1970s, many groups have found that
blood basophils from active chronic spontaneous urticarial
(CSU) subjects have reduced IgE receptor–mediated HR but
not in the HR induced via IgE receptor–independent pathways
(ionophore, 48/80, N-formyl-methionyl-leucin-phenylalanine
(fMLP), bradykinin and monocyte chemoattractant protein
1 (MCP-1), indicating a speciﬁc defect in the FceRI path-
way.59–62 CSU subjects can be segregated based on the
bimodal distribution of their basophil FceRI-induced HR pro-
ﬁles, a feature that is stable during active disease.60,63 Fifty
percent of CSU subjects have signiﬁcant reductions in their
blood basophil IgE receptor–induced HR (,10% of total his-
tamine content) and are deﬁned as nonresponders. The re-
maining CSU subjects have .10% basophil FceRI-induced
HR and are called responders.64 These basophil subgroups
also have altered protein levels of signaling molecule expres-
sion that reﬂects their IgE receptor functional classiﬁcation.
Blood basopenia is also unique to CSU and is correlated with
disease activity.65,66 Furthermore, basophils are found in both
lesional and nonlesional skin biopsies of CSU subjects, sug-
gesting that basopenia is related to the recruitment of baso-
phils to skin tissues.67 Systemic corticosteroid therapy, which
leads to an increase in blood basophil numbers and reduces
skin symptoms in CSU, is known to inhibit basophil recruit-
ment to the skin.66,68,69 In CSU subjects who enter remission,
basophils shift toward normalization of basophil IgE receptor–
mediated HR and correction of basopenia.60,63
DIAGNOSTIC APPROACH TO URTICARIA
The goal of diagnostic measures is to (1) identify urticaria
type and subtype and (2) identify underlying causes (in long-
standing or severe chronic sponganeous urticaria only). Urticaria
of either acute or chronic type is a common disease that
manifests with heterogeneous phenotypes. It poses a high
socioeconomic burden for patients.70 In general, a limited initial
workup is indicated, unless the clinical history dictates otherwise.
AU is more common than the chronic form and is
associated with a rapid recovery, but the identiﬁcation of its
etiology can be helpful to prevent recurrence especially when
allergy is suspected to be the cause. Although chronic
spontaneous urticaria has various etiologies and subtypes,
routine patient evaluation comprising the careful acquisition of
patient history, physical examination, and ruling out of systemic
diseases should be considered. Speciﬁc provocation and labora-
tory tests are needed to conﬁrm the underlying causes whenever
the clinical history is supportive. These extensive diagnostic
procedures should be considered on an individual basis in
patients with long-standing, severe, or persistent urticaria.
Diagnostic Approach for Patients With Acute
Spontaneous Urticaria
Although both a detailed history and physical exami-
nation remain essential, the etiology of acute spontaneous
urticaria can be suggested by a patient’s history. Upper
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respiratory tract and viral infections are the most common
etiology in children. Foods and drugs such as antibiotics
and nonsteroidal anti-inﬂammatory drugs (NSAIDs)71 can
be considered for both adults and children. In general, diag-
nostic workup is indicated only when type I allergy is sus-
pected to be the underlying cause of acute spontaneous
urticaria.
Diagnostic Approach in Patients With CSU
In patients with CSU, it is necessary to obtain a thorough
history, including all possible eliciting factors, and to identify
the signiﬁcant aspects of the disease. This initial assessment is
helpful in the identiﬁcation of the subtype of urticaria (acute vs
chronic, spontaneous vs induced). The overall duration of CSU
is likely to be longer in patients with high disease severity,
angioedema, positive autologous serum skin test (ASST)
results, or comorbidity with physical urticaria. Next, the
impact of the disease on the patient and the disease activity
should be evaluated using the urticaria activity score and the
CU quality of life questionnaire (see Quality of Life and
Patient-Reported Outcomes). The patient should be asked
about the time of onset; frequency and duration of wheals;
presence of diurnal variation; shape, size, and distribution of
wheals; associated angioedema; family and personal history of
urticaria; atopy; medications (NSAIDs, hormones, laxatives,
immunizations); and observed correlation with food and stress.
The ﬁrst step is to exclude major comorbid disorders and
physical urticaria, and the second step is to identify the under-
lying cause. Patient questioning together with physical exam-
ination and laboratory and provocation tests may be useful to
identify associated diseases and comorbidities, and in some
cases, the underlying cause. Routine laboratory testing in the
absence of a clinical history is rarely helpful in determining an
etiology for patients with CSU.72,73 Nevertheless, expert opin-
ion differs in regards to the number and type of testing appro-
priate for patients with CSU.
Routine hematological tests, including complete blood
count and liver function tests, the determination of erythro-
cyte sedimentation rate, and C-reactive protein levels may
be considered. The role for infectious agents such as Heli-
cobacter pylori in the causation of chronic urticarial is
controversial, and the evidence is weak and conﬂicting.74
Screening for thyroid autoimmunity may be considered.
Although type I allergies are a very rare cause of CSU, the
IgE-mediated mechanism may be considered in patients with
intermittent symptoms. For differential diagnosis from
patients with angioedema alone without wheals, the mea-
surement of C4 and C1 esterase inhibitor levels may be
necessary. About one third of CSU patients have aspirin/
NSAID hypersensitivity, and oral provocation tests with
aspirin are available to conﬁrm this if needed.71 Some
CSU patients improve with a food-additive-free diet, and
challenge tests with food additives may be necessary.18
The ASST is the only generally available test to screen for
autoantibodies against either IgE or the high-afﬁnity IgE
receptor. Autoimmune urticaria responds poorly to H1 anti-
histamines and often manifests as severe CSU. However,
some studies have demonstrated low sensitivity of the ASST
with a high false-positive rate. The basophil HR test is more
reﬁned but is also insufﬁciently sensitive to be applied rou-
tinely. The diagnostic workup should include physical stim-
ulation tests if physical urticaria is suspected. Ice cube or
cold water tests are used widely for cold urticaria, and exer-
cise challenge tests are used for cholinergic and exercise-induced
urticaria. To improve outcomes for CSU patients, quality of life
and psychiatric comorbidity should be considered. A skin biopsy




Second-Generation Antihistamines at Licensed Doses
Second-generation antihistamines (azelastine, bilastine,
cetirizine, desloratadine, ebastine, fexofenadine, levocetiri-
zine, loratadine, mizolastine, and rupatadine) at licensed doses
represent the mainstay of treatment for urticaria. A number
of high-quality, randomized, controlled trials have been
carried out with these drugs in patients with mild/moderate
urticaria.3,5,75 Evidence of their effectiveness is very high.
They are also safe and well-tolerated.
Comparative Efﬁcacy of
Second-Generation Antihistamines
The higher efﬁcacy of cetirizine (10 mg) over fexofena-
dine (180 mg) has been shown in a randomized, double-blind
study.76 In another multicenter, randomized, double-blind
study, levocetirizine was more effective than desloratadine.77
Bilastine and levocetirizine have been recently compared in
a randomized double-blind study and showed a similar
effectiveness.78
Finally, in a series of in vivo comparative studies
assessing suppression of histamine-induced wheal and ﬂare
responses of different second-generation antihistamines,
cetirizine and its derivative levocetirizine were always
superior to other nonsedating antihistamines in terms of
efﬁcacy.79–81 However, a new study did not demonstrate sig-
niﬁcant differences between overall inhibition of wheal or
ﬂare by 20 mg of bilastine and 10 mg of cetirizine.82 The
correlation of these in vivo comparisons with clinical efﬁcacy
is unknown. Randomized, double-blind, placebo-controlled
trials have not found relevant differences in sedation and
impaired psychomotor function between levocetirizine, cetir-
izine, and loratadine.83 Some clinical trials and postmarketing
surveillance studies found that the sedative effect of cetirizine
was greater than that of fexofenadine or loratadine.84
First-Generation Antihistamines
Double-blind placebo-controlled studies have demon-
strated efﬁcacy for several ﬁrst-generation antihistamines
in CU with overall similar efﬁcacy to second-generation
antihistamines.85–87 First-generation antihistamines have been
recommended as add-on therapy to CU patients who have had
inadequate control on second-generation antihistamines; how-
ever, studies to demonstrate efﬁcacy of this approach are
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lacking.28 Sedation and cognitive/psychomotor function
impairment are side effects of ﬁrst-generation antihistamines,
but the degree of these side effects varies between individu-
als.88 Therefore, sedating antihistamines are typically recom-
mended to be dosed as a single nocturnal dose to reduce
daytime impairment.89 Studies have shown that tolerance to
performance impairment improves while taking ﬁrst-generation
antihistamines after 3 to 5 days of treatment.85,90 Based on the
availability, cost-effectiveness, and safety of second-generation
antihistamines, ﬁrst-generation antihistamines are being now
less frequently recommended as ﬁrst-line agents.3,4,75,91,92
In other words, ﬁrst-generation antihistamines do not provide
additional beneﬁts to those obtained with nonsedating
antihistamines.
Dosing of Second-Generation Antihistamines at
Higher Than Licensed Recommendations
Many patients with CU may not respond adequately to
the recommended doses of second-generation antihistamines.
Limited data are available on dosing second-generation anti-
histamines at higher than the recommended amounts.93–96 An
open-label study of cetirizine93 and a double-blind, controlled
study of desloratadine in patients with cold urticaria96 demon-
strated that increased dosages of these second-generation anti-
histamines had greater therapeutic beneﬁts without increased
side effects. Subsequently, a double-blind multicenter study in
CU patients using desloratadine and levocetirizine was pub-
lished showing improved effectiveness with higher dosing up
to 4 times the recommended amount.97 Although a double-
blind placebo-controlled study did not show differences in
efﬁcacy between a 10 mg or 20 mg daily dose of rupatadine
in CU,98 a recent study showed that higher doses of this drug
are more effective than standard doses.99 Similar studies have
not been performed or veriﬁed with other second-generation
antihistamines. In patients with CSU, updosing of nonsedating
antihistamines increases the rate of response from about 45% to
more than 60%. Due to their good tolerability and safety pres-
ent, recommendation for patients who do not respond to stan-
dard doses of nonsedating antihistamines is to use higher doses
instead of corticosteroids as second-line treatment.
H2-Antagonists
Most studies demonstrating efﬁcacy of H2-antagonists
added to H1-antagonists in CU have been performed
with cimetidine.100–102 Studies evaluating the combination
of H1-antagonists and ranitidine in CU have yielded conﬂict-
ing results.103,104 Cimetidine’s effectiveness is believed to be
due to its ability to inhibit a number of cytochrome p450
isoenzymes involved with the metabolism of ﬁrst-generation
antihistamines, resulting in an increased plasma concentra-
tions of antihistamines like hydroxyzine.105,106 These additive
effects have not been seen with the combination of cimetidine
and cetirizine, and studies evaluating the combination of
H1-antagonists and ranitidine or famotidine have yielded con-
ﬂicting results.103,104 Thus, altogether the quality of evidence
for the use of H2 receptor antagonists in association with H1
antihistamines is low, and such association does not seem to
produce any advantage over the use of anti-H1 antihistamines
alone; however, other experts consider the combination to be
safe and affordable, sometimes effective, and preferable in its
risk–beneﬁt proﬁle to other second-line treatment options.106
Leukotriene Receptor Antagonists
The effectiveness of these drugs has been reported
in several relatively small, randomized, double-blind stud-
ies,108–112 but the results have been inconsistent.113 A recent
review on this issue concluded that leukotriene receptor
antagonists might be effective in subsets of patients with
CSU associated with aspirin or food additive intolerance or
positive on ASST but not in other patients with chronic spon-
taneous urticaria,114 although other studies do not seem to
support this view.115 Altogether, existing evidence of their
effectiveness is limited, and the grade of recommendation
for their use is low. Nonetheless, these drugs may be tried
in patients unresponsive to antihistamines in view of their
excellent safety proﬁle.
Corticosteroids
Although it is clinically recognized that oral corticosteroids
are effective for H1-antihistamine–resistant CU, controlled stud-
ies are lacking.117 In view of the potentially severe side effects
associated with long-term treatment, oral corticosteroids should
be used for short periods and at the minimally effective dose
necessary to achieve control. There is no consensus on the dose
and duration of oral corticosteroids for the management of CU,
but some recommended approaches about short-term therapy
have been published.117 Attempts should be made to ﬁnd alter-
native agents to control urticaria to avoid long-term corticoste-
roid use. In rare patients, long-term corticosteroid use may be
justiﬁed; however, patients should be monitored closely for
adverse effects of corticosteroid therapy.
One published protocol suggests using prednisone
15 mg daily (preferably 10 mg) and decrease by 1 mg (using
1-mg tablets) each week. Considerable efﬁcacy can be
achieved, and subsequent responsiveness to other modalities
can be enhanced. If higher doses are needed to signiﬁcantly
lessen symptoms, the drug should not be used.15,117 In con-
clusion, corticosteroids should be used sparingly only when
all other therapies failed, until other controller therapies can
be found that control the hives.
Anti-Inflammatory Agents
Although the evidence for efﬁcacy in the treatment of
CU for many of the following anti-inﬂammatory agents is
limited, the favorable cost and relatively safe side effect
proﬁles warrant their consideration before using more expen-
sive or more toxic agents.
Dapsone
Case reports and case series have found dapsone to be
effective in the treatment of CU, idiopathic angioedema,
delayed pressure urticaria, and urticarial vasculitis.118–124
A recent randomized, unblinded study of 65 CU patients
compared dapsone and desloratadine with desloratadine alone
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over a 3-month treatment period followed by a 3-month post-
treatment observational period.125 The dapsone-treated group
had similar reductions in urticaria scores compared with the
desloratadine monotherapy group, but 9 dapsone-treated
patients experienced complete responses, whereas none of
the control subjects did. Five of 9 responders remained urti-
caria free 3 months after discontinuing dapsone. Dapsone is
usually well-tolerated but has predictable side effects includ-
ing dose-related anemia. Less common adverse effects
include peripheral neuropathy, rash, gastrointestinal com-
plaints, hepatotoxicity, and rarely methemoglobinemia, blood
dyscrasias, or the syndrome of drug rash with eosinophilia
and systemic symptoms.126 Before the initiation of dapsone
therapy, glucose-6-phosphate dehydrogenase levels should be
normal as the risk of severe hemolysis is increased in glucose-
6-phosphate dehydrogenase–deﬁcient patients. Laboratory
monitoring for anemia and hepatotoxicity is recommended
for patients on dapsone.127
Sulfasalazine
Case reports and case series have suggested that
sulfasalazine is efﬁcacious in patients with CU and delayed
pressure urticaria.128–130 A retrospective observational study
of 19 CIU patients demonstrated signiﬁcant improvement in
14 of 19 patients with more modest beneﬁt in 4 additional
patients.131 Therapeutic response occurred within 1 month,
and doses above 2 g/day had no additional beneﬁt. As stated,
most references to sulfasalazine use in CU are case reports or
uncontrolled studies.
The most common side effects include nausea, vomiting,
dyspepsia, anorexia, and headache.132 These symptoms typi-
cally occur early in therapy and are more common in patients
taking .4 g/day, which is beyond the dose recommended for
the treatment of CU. Slow-dosing escalation regimens over
several days may reduce the gastrointestinal effects. Hemato-
logic abnormalities, proteinuria, and hepatotoxicity are uncom-
mon, but laboratory monitoring for these adverse effects is
recommended.133
Hydroxychloroquine
Limited data are available on the use of hydroxychlor-
oquine in CU. A case report suggested efﬁcacy in a patient with
hypocomplementemic urticarial vasculitis.134 A randomized,
blinded, placebo-controlled study of 21 CU subjects demon-
strated signiﬁcant improvement in the quality of life but only
trends toward improvement in urticaria activity scores or reduc-
tion in other medications.135 Hydroxychloroquine is generally
well-tolerated with the most worrisome adverse effect being
retinopathy. The risk of retinopathy from hydroxychloroquine
is exceedingly rare.136 Almost all cases have occurred in high-
risk individuals who have used the drug .5 years. The most
recent American Academy of Ophthalmology137 guidelines
recommend that all patients have a baseline ophthalmologic
examination within the ﬁrst year of starting the drug and annual
screening after 5 years or a cumulative dose of .1000 g. For
higher risk patients including the elderly and patients with kid-
ney/liver dysfunction, retinal disease, or maculopathy, annual
eye examinations are recommended.
Colchicine
CU patients with neutrophilic inﬂammation responded
to colchicine,138 and case reports suggest its efﬁcacy in
patients with urticarial vasculitis.139–141 Colchicine is gener-
ally well-tolerated with the most frequent adverse effect being
diarrhea. High doses can cause bone marrow suppression, and
long-term use can rarely cause myopathy and neuropathy.
Immunosuppressive Agents
Calcineurin Inhibitors
Case reports and case series have described beneﬁt
of cyclosporine to patients with CU unresponsive to anti-
histamines.142–144 There are 4 published randomized,
double-blinded, controlled trials investigating the therapeutic
utility of cyclosporine for patients with CU/angioedema who
had failed second-generation antihistamines.145–148 Although
the results of these studies show favorable effects, the side
effects of this agent may outweigh its beneﬁts. Further research
is necessary to determine the effect of cyclosporine in the
treatment of more well-deﬁned refractory CU patients. The
optimal dose of cyclosporine has not been adequately delin-
eated. Investigators have initiated therapy using both higher
doses (eg, 3–5 mg/kg per day) versus lower doses (200 mg/
day). During the treatment period, blood pressure, kidney
function, and liver function should be regularly monitored.
In a follow-up study after stopping cyclosporine, complete
remission lasted up to 9 months in about 50% of patients
and a decreased number of ﬂare-ups and a restored response
to antihistamine treatment was observed in some subjects.148
Recently, a low-dose, long-term maintenance therapy for up to
2 years has been suggested for those who show a marked
propensity to relapse after discontinuation.149
Tacrolimus, another calcineurin inhibitor, has been
reported in an observational study to be effective in CU
patients unresponsive to antihistamines, one of which was
also unresponsive to cyclosporine.150
Other Immunosuppresive Agents
Several other immunosuppressive drugs, including meth-
otrexate, cyclophosphamide, azathioprine, sirolimus, and myco-
phenolate mofetil, have been used to treat H1-antihistamine–
resistant CU. However, most experience relies on case reports
or single-center uncontrolled studies. Two recent retrospective
studies have been published showing that methotrexate at
a weekly mean dosage of 15 mg is effective and safe in the
majority of CU patients who are not responsive to conventional
therapy.151,152 According to Perez et al,151 methotrexate exerts
anti-inﬂammatory and immunosuppressive effects and may
therefore beneﬁt CU independently of the pathogenic mecha-
nism, whether associated with autoantibodies. The efﬁcacy of
intravenous and oral cyclophosphamide153,154 and azathio-
prine155 has been demonstrated in case reports who had antihis-
tamine-resistant CU and were positive on ASST. Both drugs
have been successfully employed in the treatment of urticarial
vasculitis.156 Mycophenolate mofetil seems to be a useful treat-
ment option for patients with CU who do not respond to anti-
histamines and/or corticosteroids with experience limited to
observational studies.157,158
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Biological Agents
Omalizumab
Recently, a growing number of studies evaluating the
effectiveness of omalizumab (humanized monoclonal anti-IgE
antibodies) in different subsets of antihistamine unresponsive
CU/angioedema patients have been reported.36,39,159–166
Although the current experience with omalizumab in the treat-
ment of CU is encouraging, rare cases of omalizumab failure
have been reported.167 Several multicenter, randomized,
placebo-controlled, dosing studies are still in progress to assess
the role of this agent, but some have very recently appeared in
the literature.38,40 Efﬁcacy and side effect proﬁle potentially
make omalizumab the future drug of choice for refractory
chronic spontaneous urticaria. The main limitations of omali-
zumab treatment include limited availability, high-cost, and
long-term clinical beneﬁts.
Intravenous Immunoglobulin
Success in CU was ﬁrst reported in an open-label trial
of 10 CU patients with positive ASST and basophil HR
tests who failed other therapies at a dose of 0.4 g/kg per day
for 5 consecutive days168; 9 of 10 patients improved with
3 patients experiencing prolonged remission after a 3-year
follow-up. Other case reports and case series have found
intravenous immunoglobulin (IVIG) to be effective,169,170
whereas others have not.171,172 IVIG can be dosed in several
ways, but the optimal dose, number of infusions, and fre-
quency are not fully delineated. One study using low-dose
IVIG (0.15 g/kg every 4 weeks) resulted in an improvement
in 26 of 29 patients including 19 who experienced complete
remission.173 IVIG may be effective for delayed pressure
urticaria and angioedema,174 solar urticaria,175 and urticarial
vasculitis.176 IVIG is relatively safe with predictable infusion-
related adverse reactions including headache, myalgias, and
nausea and rarely anaphylaxis, aseptic meningitis, or renal
failure. In general, IVIG should be reserved for patients
refractory to other alternative therapies.
Other Therapies
Anticoagulants have recently been found to be effective
in patients with refractory CU.50–52,177–180 One recent study
reported that low–molecular weight heparin was effective in
a subset of refractory CU patients with elevated D-dimer
levels.181 Despite this increasing evidence, anticoagulant therapy
cannot be presently recommended as a routine treatment for CU.
Other therapies have been reported as cases or case series
for the treatment of CU, and very little information is known
about their effectiveness and therefore is not recommended for
routine use. These treatments include theophylline, androgens,
b-agonists, nonsteroidal antinﬂammatory drugs, tumor necrosis
factor-a inhibitors, calcium channel blockers, gold, plasmaphe-
resis,32 phototherapy, and autohemotherapy.
NOTE ABOUT THE QUALITY OF EVIDENCE AND
STRENGTH OF RECOMMENDATION GRADING
All existing systems to grade the quality of evidence
and the strength of recommendations have their own weak-
nesses. In the present article, the GRADE system182 has been
adopted. One of the problems of this system is that in its
original form, it has only 2 strengths of recommendation, that
is, weak or strong. Thus, to indicate which “weak recommen-
dations” are stronger than others (ie, have a recommendation
in between weak and strong or in other words “moderate”) the
special notation “**” has been adopted (see Table 2).
THE PROGNOSIS OF URTICARIA
AND ANGIOEDEMA
The prognosis of AU is excellent, with most cases
resolving within days; however, the prognosis of CU is variable.
If angioedema is present, the prognosis is worsened (see below).
CU is more common in adults and unusual in children.
Acute Urticaria
Few studies are available on the prognosis of AU.183,184
Two studies indicated that 20 to 30% of young children with
AU are at the risk of chronic or recurrent urticaria.185–187
More concerning than repeated episodes of AU is the pro-
gression of the disease to CU.188,189
Hospital admissions for urticaria were approximately 3
times higher in children aged 0 to 4 years than for other ages.
Between 1993–1994 and 2004–2005, there were signiﬁcant in-
creases in the rate of hospital admissions for urticaria in all ages.1
In adults, longer disease duration is an important risk
for poorer prognosis.190 AU causes discomfort, but not
mortality, unless associated with angioedema of the upper
airways.191–193 Morbidity depends on severity and duration.
One study found urticaria patients can have as much psycho-
logical, social, and occupational distress as patients awaiting
triple coronary artery bypass surgery.194 If a patient continues
to be exposed to a trigger, urticaria may become chronic.
Chronic Urticaria
Studies in multiple countries report complete resolution in
approximately one third of patients with idiopathic CU for more
than 1 to 5 years and partial improvement in another third.195
Spontaneous remission occurs in 30 to 50% of patients
within 1 year, and another 20% within 5 years. Nearly 20% of
patients still have symptoms after 5 years. Almost half of
patients with CU lasting 6 months are likely to have wheals
10 years later.196 Those with more severe symptoms may have
longer lasting disease. A retrospective study of 372 patients
with severe urticaria described resolution of symptoms in
29% of patients after 5 years and 44% after 10 years.197,198
Patients younger than 30 years with more severe
symptoms, or symptoms with physical causes, fared less
well.195 For those with physical urticarias, their condition
may be better measured in decades, rather than years, but
can typically be controlled.199
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In an Amsterdam prospective study of 220 patients with
CU and angioedema,200 35% of patients had complete reso-
lution of symptoms 1 year after enrollment. Resolution rates
ranged from a high of 59.6% in patients with idiopathic urti-
caria-angioedema to a low of 16.4% in patients who had
urticaria with a physical cause.195 In a Netherlands retrospec-
tive study, 544 cases with CU and angioedema identiﬁed the
mean age at presentation to be 35 years, and patients had been
symptomatic an average of 5 years.201
A prospective study published in 2004 found that
duration of urticaria was longer in patients who had associated
angioedema or positive anti-IgE receptor antibody.202 Disease
duration is likely to be longer in cases of angioedema, a com-
bination with physical urticaria, positivity in the ASST
(autoreactivity), and a high disease severity.6,203
Malignancy has been linked with urticaria and may
suggest a relapse of the malignancy. There is no strong
evidence to conﬁrm an association between malignancy and
uncomplicated CU, except occasionally in urticarial vasculitis
and, more frequently, in acquired C1 esterase inhibitor
deﬁciency.204,205 Although mortality may occur because of
laryngeal edema, death is more likely due to complications of
the associated disorder.206
Angioedema
In cases involving recurrent angioedema without urticaria,
hereditary and acquired angioedema must be differentiated.
Acquired angioedema includes, among other etiologies, ACE
inhibitor–induced angioedema and angioedema due to acquired
C1-inhibitor deﬁciency. Much like CU, the majority of cases
involving acquired angioedema, with some exceptions such as
ACE-inhibitor angioedema, can be adequately controlled with
daily doses of nonsedating antihistamines.207 Angioedema of
the upper airway can be life threatening. In rare cases, angioe-
dema may develop into anaphylaxis.208
In Australia, over an 8-year period, there were 106 deaths
associated with anaphylaxis or angioedema. According to this
study, there was a continuous increase in the rate of hospital
admissions for angioedema (3.0% per year) and urticaria (5.7%
per year). The rate of hospitalization for angioedema was
highest in persons aged 65 years and older and lowest in
children between 5 and 14 years. Although the rate of hospital
admissions for angioedema remained relatively constant for
most age groups between 1993–1994 and 2004–2005, the rate
in persons aged 65 years and older doubled from 10 to 20 per
100,000 population. This represented an average annual
increase of 5.6% in the rate of admissions for angioedema in
this older age group. For those aged 15 to 34 years, the average
annual increase was 4.3%. There was no signiﬁcant change in
the rate of hospital admissions for angioedema in those younger
than 15 years or from 35 to 64 years. Among older persons,
angioedema is becoming an increasing problem.1
The prognosis for patients with acquired angioedema
associated with C1 inhibitor deﬁciency is variable and depends
on control of the underlying disorder. Even with appropriate
treatment of the underlying disease, patients may only
temporarily be free of symptoms. In several small studies,
patients with acquired angioedema associated with C1 inhib-
itor deﬁciency had approximately 20% incidence of non-
Hodgkin lymphoma.206
In summary, the prognosis of urticaria and angioedema
is improved with prompt and proper treatment. Using avail-
able medications, the condition is usually manageable.
TABLE 2. Quality of Evidence and Strength of Recommendation for Use of Intervention Based on the GRADE System182
(Updated to August, 2011)
Drug Quality of Evidence Strength of Recommendation
Second-generation antihistamines (at licensed doses) High Strong (1)
First-generation antihistamines High Strong (2)
Second-generation antihistamines (at higher than
licensed doses)
Moderate Weak (1)
Anti-H2-antihistamines as add-on therapy Moderate Weak (1)
Oral corticosteroids (short course) Low Weak (1)
Oral corticosteroids Very low Strong (2)
Leukotriene receptor antagonists (as add-on therapy) Low Weak (1)
Anti-inﬂammatory agents (dapsone, sulfasalazine,
hydroxychloroquine, colchicines, mycophenolate
mofetil)
Low-very low Weak (1)
Immunosuppressive agents
Cyclosporine Moderate Weak (1)*
Methotrexate Very low Weak (1)
Cyclophosphamide Very low Weak (1)
Biologic agents
Omalizumab, Moderate Weak (1)*
IVIG Low Weak (1)
(1), recommendation for medication; (2), recommendation against medication.
*Although the recommendation is “weak” according to the GRADE approach, it is stronger than in other cases based on the quality of existing evidence.
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URTICARIA AND ANGIOEDEMA IN CHILDREN
Prevalence
There is little published information on the prevalence,
diagnosis, or management of urticaria in children. Even in the
current EAACI/GA2LEN/EDF/WAO and BSACI guidelines
on the diagnosis and management of urticaria,3,4 the section
on paediatrics is small.
A very recent review on urticaria in children was
published by Church et al,209 which compared published
studies of prevalence of urticaria in adults and in children
and noted that CU in children appears to be less common.210
In the United Kingdom, the incidence of childhood urticaria
was around 3.4%,188 in Germany 4.4%,147 and in Denmark
about 5.4%.211 In children, most episodes of urticaria appear
to be acute, and CU has been reported to affect only 0.1 to
0.3% of children in the United Kingdom.212 By comparison,
13% of Thai children with a diagnosis of urticaria have been
reported to have CU.213
Etiology
For AU, infections appear to play a more signiﬁcant
role in infants214 and children.215
Food Allergy and Parasite Allergy
In a recent study in 80 children with CU, dietician
supervised elimination diets of all candidate food allergies
suspected by the history and speciﬁc IgE levels did not result in
any participants reducing or eliminating their requirement for
ongoing antihistamine medication, suggesting that food allergy
is not an important etiological factor in CU in childhood.216
Antibodies to the IgE Epsilon Receptor
Three independent studies have shown that CSU in
children can be caused by autoreactivity as assessed by use of
the ASST.216–218
Food Additives
In 1 pediatric study of children between 3 and 17 years,
12 of 16 (75%) were diagnosed with additive-induced urticaria,
occurring mainly in response to coloring agents, preservatives,
monosodium glutamate, and sweeteners, in the absence of
atopy.219
Infections
Although some authors suggest that urinary tract infec-
tions followed by Chlamydia pneumonia and H. pylori220 were
associated with chronic spontaneous urticaria in children, others
believe that chronic infection is unlikely to have a signiﬁcant
role in urticaria in children.188,217 Wedi et al221 has suggested
that in children recurrent upper respiratory infection, pharyngi-
tis, tonsillitis, and sinusitis with streptococci and staphylococci
is associated with CU, and remission of urticarial symptoms has
been noted with antibiotic therapy.
Other Immune Diseases
Although thyroid autoimmunity occurs as a comorbidity
in between 14 and 33% of adults with chronic spontaneous
urticaria,209 it has been reported to be much lower in children
(about 4.3%).222 A small association between CU and celiac
disease was also reported in 5% of children with CU.223
Natural History of the Disease
In the cohort of pediatric patients with chronic sponta-
neous urticaria followed for 3 years by Du Toit et al,216 no
clear predictions of disease remission were established; 25%
experienced remission in the 3-year period, and this was unre-
lated to the presence or absence of associated autoimmunity
to the IgE Fce receptor.
By contrast, 58% of children became free of urticarial
symptoms in a study of 94 children, of whom 29 were
considered “idiopathic” after 16 months, whereas the remain-
ing 42% continued to have recurrent symptoms.224 A very
recent study by Sahiner et al225 in 2011 found that recovery
was observed in 50% of children at 60 months.
Treatment
In view of the marked adverse effects on the quality of
life, ability to play, and school attendance, treatment is
necessary in nearly all children with chronic spontaneous
urticaria. CU negatively affects school performance. First-
generation antihistamines, although effective, are no longer
recommended for the management of children with chronic
spontaneous urticaria.209
Second-generation antihistamines are the treatment of
choice. In a study of antihistamine treatment given to infants
with atopic dermatitis,226 continuous treatment with levoce-
tirizine signiﬁcantly reduced exacerbations of concomitant
urticaria in this cohort (5.8% vs 16.2% in a placebo group).
A follow-up study with levocetirizine showed a 60% reduc-
tion in the number of urticarial episodes.227
Pediatric suspensions of desloratadine, fexofenadine,
rupatadine, and loratadine are available, but pediatric studies
on these second-generation H1 antihistamines, which are
effective in adult urticaria particularly at standard and higher
than standard doses, are still to be performed.
In the follow-up study by Du Toit et al,216 all children
responded well to daily treatment with cetirizine, and very
few required a short course of prednisone to control symp-
toms, irrespective of whether they had autoantibodies to the
IgE receptor or not.
There are no pediatric studies on the use of leukotriene
receptor antagonists, H2 antihistamines, cyclosporine, or
omalizumab for the treatment of urticaria. Experience with
cyclosporine in children with severe resistant chronic spon-
taneous urticaria is similar to that reported in adults. It has
been found to be safe and highly effective when indicated.228
There is no evidence in the literature that children with
persistent spontaneous urticaria, who do not go into sponta-
neous remission within a few years, go on to develop other
autoimmune diseases. Long-term follow-up studies (more
than 10 years) of urticaria in children are awaited.
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URTICARIA AND PREGNANCY
Urticaria may occur in pregnancy as a result of any of
the causes seen in nonpregnant women. In women with
preexisting CU, the condition may worsen in some patients
and appears to improve in others.229
New-Onset Urticaria
Urticaria occurring only in pregnancy is rare, but when
it occurs, it suggests that sensitivity to hormones may be the
basis of the condition. It may recur with each pregnancy in
a predisposed woman. Gestational urticaria must be distin-
guished from other pruritic dermatoses of pregnancy, such as
prurigo of pregnancy, PUPPP, PEP, or autoimmune pro-
gesterone dermatitis of pregnancy.
Prurigo of Pregnancy (Prurigo Gestationis
of Besnier)
This condition is relatively common occurring in
approximately 1 in 300 pregnancies. Characteristically, it
begins in the second or third trimester. Patients usually
present with marked excoriations with erythematous nodules
or papules on the extensor surfaces of the limbs and the trunk.
Usually total remission occurs immediately postpartum.
Management is usually with topical corticosteroids.230
PUPPP (Pruritic Urticarial Plaques and Papules
of Pregnancy) or PEP (Polymorphic Eruption
of Pregnancy)
PUPPP occurs in 1 in 160 to 1 in 300 pregnancies and
usually presents in the third trimester.231,232 It is seen most
commonly in ﬁrst pregnancies and with multiple births.233 It
presents typically with erythematous papules within the striae
and these spread to extremities but spare the face, palms, and
soles. Lesions may coalesce to form urticarial plaques. This
condition causes extremely severe pruritus. Most commonly,
it resolves within 2 weeks of delivery but may resolve before-
hand. Occasionally, it may worsen postpartum. Management
consists in relieving the distressing symptoms. Topical ste-
roids and antihistamines are initially used; some patients
require systemic corticosteroids because of severe pruritus.
Autoimmune Progesterone Dermatitis
of Pregnancy
This condition is similar to the rare autoimmune
progesterone urticaria that occurs in a cyclical pattern in
nonpregnant women. In pregnancy, it is characterized by
a papulopustular eruption, transient arthritis, eosinophilia, and
delayed hypersensitivity to intradermal progesterone. It may
be associated with spontaneous abortion.234–236
Management
Pregnant women with urticaria should be treated with
the least amount of medication possible. Most patients can be
treated with H1 antihistamines alone, with occasional short
courses of oral glucocorticosteroids (GCS) for severe ﬂares.
Antihistamine treatment is the mainstay of management
in urticaria. The intense itch experienced by patients demands
relief, whereas soothing baths and emollients offer minor
comfort; most patients require symptomatic relief with an
antihistamine.
There are no oral antihistamines with a category
A listing for pregnancy. Categories are based on the results
of animal studies, human data, and whether the use of the
drug has a positive risk–beneﬁt ratio in pregnancy. Category
“B” drugs possess reassuring animal data, but there are no
controlled clinical human trials.
A number of studies237–240 have evaluated the safety of
antihistamines in pregnant women. Most women who require
regular antihistamines for control of CU will prefer treatment
with second generation, nonsedating drugs.
Chlorpheniramine, loratadine, cetirizine, and levocetir-
izine have all been assigned category B by the US Food and
Drugs Administration. As with any medication use, antihist-
amines should only be used if clearly needed and when the
beneﬁts outweigh the potential risk to the fetus. Use of the
lowest dose that gives relief is advisable. There are several
thousand reports of chlorpheniramine use in pregnancy with
no evidence of increased incidence of congenital abnormality.
No rate of increased congenital defects was reported in
prospectively collected data from 1769 women exposed to
loratadine. Small sample size studies are available for cetirizine,
and there is a meta-analysis available for loratadine.237,238
Hydroxyzine is the only antihistamine speciﬁcally contraindi-
cated in pregnancy in the product literature.
The second-generation antihistamines of choice in preg-
nancy are loratadine 10 mg daily or cetirizine 10 mg daily
because there is a body of evidence of their use in pregnancy
with reassuring safety proﬁles.240
In special cases where a sedative effect is required along
with an antihistaminic effect, chlorpheniramine is the ﬁrst-
generation antihistamine of choice. Recommended dosing is
4 mg 3 to 4 times a day. Diphenhydramine shows higher
efﬁcacy and can be used as an alternative to chlorpheniramine
if the use of a ﬁrst-generation antihistamine is being considered.
Antihistamines and Breast-feeding
Signiﬁcant amounts of some antihistamines are detected
in breast milk. Again, antihistamines should only be used
during lactation when the beneﬁt outweighs the potential
harm to the infant, and in this circumstance, use the lowest
dose possible for the shortest duration to give relief from
symptoms. Loratadine and cetirizine appear safer than others
with very low levels recorded in breast milk.241,242
Corticosteroids
Systemic corticosteroids may be required periodically
to gain temporary control of symptoms during severe
exacerbations of urticaria that signiﬁcantly impair the quality
of life. These rescue courses are generally added to the
medications the patient is already taking.
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The optimal dose and duration of GCS used for
urticarial exacerbations has not been systematically studied,
and recommendations vary among specialists. In addition,
patients differ in their responsiveness to GCS in both the dose
and duration of treatment required to control symptoms.
Because of their importance in the treatment of a variety of
inﬂammatory conditions, systemic GCS have been used fairly
extensively during pregnancy.
Three potential areas of concern have been raised:
congenital malformations (primarily cleft palate), neonatal
adrenal insufﬁciency, and low birth weight.243 The combined
results of 5 large studies (2 surveillance and 3 case–control
studies) found that the risk of oral clefts is approximately
doubled.244–248 However, the absolute risk is low. Because
palatal closure is usually complete by the 12th week of preg-
nancy, the risk is limited to administration during the ﬁrst
trimester.
Neonatal adrenal insufﬁciency following maternal admin-
istration of steroids is unusual. The rapid maternal metabolism
of prednisolone binding to serum proteins and conversion to
inactive metabolites by placental 11 beta-hydroxysteroid dehy-
drogenase results in relatively low fetal compared with maternal
concentrations.249 As a result, the fetal pituitary is rarely sup-
pressed in mothers taking GCS.248 However, long-term high
doses will suppress the fetal adrenal glands.
Multiple studies have observed low birth weight in
offspring of animals given GCS during pregnancy. However,
this association has been rarely reported in humans.243 It is
difﬁcult to draw conclusions regarding the effects of GCS on
fetal growth because of variability in the dose, duration, and
type of steroid and the confounding effects of the underlying
maternal disease on the pregnancy. GCS have the potential
for exacerbating pregnancy-induced hypertension, gestational
diabetes, and preterm delivery from premature rupture of
membranes.250 Thus, women at risk should be appropriately
monitored.
Corticosteroids and Breast-feeding
Low levels of prednisone and prednisolone can be
measured in breast milk. A nursing infant of a mother
consuming a daily dose of 80 mg of prednisolone would
ingest ,0.1%, which is equivalent to ,10% of endogenous
cortisol production.249 As a result, although it may be reason-
able to delay breast-feeding for several hours after ingesting
prednisone, it appears to be safe during breast-feeding.251
QUALITY OF LIFE AND
PATIENT-REPORTED OUTCOMES
During the past 20 years, relevant progresses have been
made in deﬁning and evaluating PROs, with growing recog-
nition of their importance in health outcomes research. The
expression PROs refers to all health-related reports coming
from the patient, without involvement or interpretation by
a physician or others252 [ie, health-related quality of life
(HRQoL), symptoms, illness perception, satisfaction, well-
being, perceived disease control].
PROs have recently gained great attention in clinical
research and by regulatory bodies due to their relevance in the
overall treatment efﬁcacy assessment.253–255 A critical aspect
in the management of CU is its impact on the patient’s daily
experience. The classical symptoms (pruritus, wheals, angioe-
dema) may affect sleep and concentration, interfere with life
activities, and cause embarrassment. Furthermore, because of
the presence of exacerbations, the unpredictability of attacks,
the need to take medication, and change habits and lifestyle,
CU patients may experience anxiety, tension, and irritability.
Although CU represents a problem that interferes with sub-
jective well-being and daily life, its evaluation has usually
focused on clinical end points. As recently underlined,256
the literature data about CU from a subjective viewpoint
remain poor, and most available articles consider mainly
2 PROs: HRQoL and symptoms.
HRQoL and CU
HRQoL Assessment
HRQoL in CU has been assessed by generic,
dermatologic-speciﬁc, and disease-speciﬁc tools. Several generic
tools have been used to compare HRQoL of CU patients and
healthy subjectsdMedical Outcomes Study, SF-36,257,258 World
Health Organization QOL-Brief (WHOQoL-BRIEF)259dand
CU patients and patients with other diseasesdNottingham
Health Proﬁle.194 Although generic instruments permit compar-
ison across different health conditions, they are less suitable for
the assessment within a speciﬁc disease.
The available questionnaires aimed at assessing
HRQoL in skin diseases, the Dermatology Quality of Life
Index,260 and the SKINDEX261 allow comparisons between
different dermatological conditions but are not speciﬁcally
developed for CU.
The Chronic Urticaria Quality of Life Questionnaire is
the only validated speciﬁc instrument for CSU and was
originally developed in Italian,262 German,263 Spanish,264
Polish,265 and Turkish.266 Sixteen validated versions are
now available.
Impact of CU on HRQoL
Available data show that from a subjective viewpoint,
CU is more than an annoying disease. CU subjects report
lower HRQoL when compared with healthy subjects or with
patients suffering from other medical conditions. A pioneer
study by O’Donnell et al168 compared HRQoL of CU subjects
and patients suffering from coronary artery disease. Surpris-
ingly, although patients with ischemic heart disease referred
more limitation in mobility, CU patients reported more severe
sleep problems. Energy, social isolation, and emotional reac-
tions scores showed similar results between the 2 groups.
Furthermore, HRQoL levels in patients with chronic
spontaneous urticaria are lower than in healthy subjects and in
patients with respiratory allergy.257 A study by Poon et al267
focused on the extent and nature of disability extent and nature
in different types of urticaria, showing a large variation in
HRQoL scores within different urticarial subsets. In particular,
subjects with delayed pressure and cholinergic urticaria
WAO Journal  November 2012 Diagnosis and Treatment of Urticaria and Angioedema
 2012 World Allergy Organization 137
showed HRQoL impact comparable with severe atopic der-
matitis patients and higher than patients with psoriasis, acne,
and vitiligo.
More recently, an article by Staubach et al268 showed
that when compared with healthy subjects, CU patients
reported markedly reduced HRQoL. This occurred regardless
of age, sex, duration of the disease, and the presence or
absence of angioedema. The presence and the severity of
psychiatric comorbidities were associated with a more pro-
nounced reduction of HRQoL. Recent studies conducted both
in the general population and in outpatients in different coun-
tries conﬁrmed that CU impacts HRQoL signiﬁcantly.12,269
As yet, the effect of treatment on HRQoL of CU
patients has been explored only in 11 trials.77,78,97,111,270–276
The results of these studies, although different in respect to
the drug evaluated, study design, population characteristics,
and questionnaire used, indicate an improvement in HRQoL
after treatment.
CU and Symptoms
CU symptoms can be speciﬁcally evaluated with the
Urticaria Activity Score.277 This is the unique validated
instrument for measuring and monitoring disease activity in
CU. The use of Urticaria Activity Score in clinical practice,
trials, and therapy effectiveness analyses4 is recommended by
the current EAACI/GA2LEN/EDF guidelines.
Actions To Be Taken
Although PROs evaluation is relevant for a more global
comprehension of a disease and its treatment, the available
literature on CU is still poor. The following unexplored areas
should be further investigated:
• Other PROs besides HRQoL and symptoms
• CU impact on caregivers and partners
• Impact of treatment on HRQoL by a speciﬁc
questionnaire
• Relationships among different PROs and between PROs
and psychological variables




According to the current international EACCI/GA2LEN/
EDF/WAO guidelines on urticaria,4,5 physical urticaria is
deﬁned as a special group of urticaria subtypes, where wheals
and/or angioedema are elicited by external physical stimuli.
Physical urticaria needs to be distinguished from both
spontaneous urticaria and other inducible urticaria types, such
as aquagenic urticaria or cholinergic urticaria, where wheal
formation is not induced by a physical stimulus. Physical
urticarias usually have a chronic course, but patients can be free
of symptoms for weeks or months when the physical stimulus is
avoidable and avoided. This is a clear-cut difference to chronic
spontaneous urticaria. One point of confusion in the past has
been between physical urticaria and cholinergic urticaria.
Cholinergic urticaria symptoms can be elicited through a hot
shower or bath. The underlying mechanism in cholinergic
urticaria, however, is not the external stimulus but the increase
in body core temperature; cholinergic urticaria can also be
elicited by exercise or emotional distress and is, therefore,
included in the urticaria subgroup “other inducible urticarias.”
Table 1 (see section Deﬁnition and Classiﬁcation)
shows a summary of the physical urticaria subtypes and elic-
iting factors.
Diagnosis in Physical Urticaria
Although the current international guidelines on the
classiﬁcation, deﬁnition, and diagnosis of urticaria give general
recommendations, more detailed recommendations for diagnos-
tic testing in physical urticaria are published in the “European
guideline deﬁnition and diagnostic testing of physical and cho-
linergic urticariasdEACCI/GA2LEN/EDF/UNEV consensus
panel recommendations.”278
A general principle in the diagnosis of physical urticaria
is to mimic the physical stimulus, which leads to the
formation of wheals and angioedema and at the same time
if possible determine the threshold. Threshold measurements
are important because they can help to give the patient
practical advice on how to avoid or reduce above threshold
stimulus exposure. Threshold testing also allows for the
objective evaluation and monitoring of patients who receive
treatment. Figure 1 shows the recommended provocation tests
for physical urticaria (modiﬁed from Magerl et al278).
When performing provocation tests in patients with
physical urticaria, it is recommended to have the same
standard of emergency treatment available as for other kinds
of allergy skin testing because rare cases of systemic
anaphylactic reactions, especially in cold urticaria, have been
described.
Severity of Disease and PROs
Physical urticaria can vary considerably in severity
between individuals. In a number of patients, signs of physical
urticaria only occur with unusually strong external stimulation
of the skin, for example, very cold, windy, winter days in cold
urticaria, and depending on the usual geographic location and
everyday living habits, the required strength of the stimulus to
elicit symptoms is not usually reached. However, in other cold
urticaria patients, the eliciting temperature of the skin can be as
high as 288C, a temperature which is easily reached in usual
daily activities in moderate climates, and even in warm cli-
mates, if there is a mild wind because wind chill temperature
increases the cooling effect on the skin. In cold urticaria, sys-
temic reactions have been described in the case of a rapid
change of skin temperature, for example, when patients jumped
into cold water. Another risk factor in cold urticaria is the rapid
ingestion of cold food such as ice cream or cold beverages,
which may lead to swellings of the upper airways and in the
esophagus and to systemic histamine liberation and subsequent
anaphylactic reactions.
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Physical urticaria can also have an impact on occupa-
tion. It has been recognized as an occupational disease
(eg, vibratory urticaria/angioedema can be the reason for
disability in construction workers).
Management of Physical Urticaria
A general principle of the international urticaria guide-
lines on the management of urticaria is the identiﬁcation and
elimination of the underlying cause and/or trigger.5 Although
in the majority of physical urticarias, the underlying cause is
unknown and cannot, therefore, be eliminated, avoidance of
a known trigger can be very useful.
With the exception of cold contact urticaria where in rare
cases infectious diseases, such as hepatitis, have been described
as an underlying cause, it is not recommended to invest too
many resources into the investigation of causes. In physical
urticaria, the routine diagnostic program should be limited at
the most to differential blood count and the determination of
erythrocyte sedimentation rate. However, with the identiﬁca-
tion of the eliciting trigger, it is in many cases easy to help
the patient by in detail explanation of the possibilities for
avoidance. For example, pressure is deﬁned as force per area
and simply increasing the size of a handle of a bag may help in
patients with pressure urticaria to avoid symptoms.
The treatment in physical urticaria is aimed at the
prevention and reduction of symptoms. This follows in
general the algorithm, which has been published for urticaria
in the international consensus guidelines (Fig. 2).
The level of evidence for ﬁrst-line treatment with
nonsedating antihistamines is very good both in chronic
spontaneous urticaria and physical urticaria. The updosing of
nonsedating antihistamines has been widely studied in
physical urticaria.
Thus, the level of evidence to use higher than standard
doses as the preferred second-line treatment is very high in
this group of urticarias. Siebenhaar et al279 studied the impact
of increasing the dose of desloratadine from 5 mg up to 20 mg
FIGURE 1. A, Provocation testing for
physical and cholinergic urticaria. B,
Treshold testing for physical urticaria.
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in cold urticaria and showed a clear dose-dependent response,
which supports the recommendation to increase the antihista-
mine dosage in those patients who do not show sufﬁcient
responses to standard doses.
In general, however, the level of antihistamine treatment
required may be different from day to day depending on the
strength of the external stimuli and patients’ needs to be very
thoroughly counseled on the daily use of the drug treatment.
Alternative treatments in physical urticaria have only
been scarcely studied and knowledge needs to be
extrapolated from what we know from chronic spontaneous
urticaria. However, physical urticarias are distinct from other
urticaria subtypes in that it is possible to achieve a reduction
of repetitive mast cell responses to the speciﬁc physical
stimulus by long-term controlled exposure to the stimulus.
For example, in cold contact urticaria, the occurrence of
symptoms can be prevented by administering daily cold
baths, and for solar urticaria, UV light treatment can raise UV
tolerance. However, this kind of treatment is time consuming
for the patient and in the case of cold bath is not always very
FIGURE 1. Continued.
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well liked. Furthermore, it is recommended to start at the
threshold level and increase slowly the strength of the
physical stimulus because generalized reactions may occur.
DISSEMINATION AND IMPLEMENTATION OF
THE POSITION PAPER
The WAO urticaria and angioedema position paper is
being published in the World Allergy Organization Journal
(WAO Journal) at www.WAOJournal.org to facilitate rapid
access by all 3000 WAO members. The WAO Member Soci-
eties are encouraged to contribute with the dissemination of
this position paper through discussion at national and inter-
national meetings, and translation and publication in national
allergy society journals.
SUMMARY
This Position Paper presents recommendations for the
proper diagnosis and treatment of urticaria and angioedema,
highly prevalent diseases in all areas of the world. Although
there have recently been important advances in the elucida-
tion of the pathogenesis, allowing the implementation of
innovative diagnostic and therapeutic procedures for patients
suffering urticaria, the basic mechanisms remain elusive.
Second-generation nonsedating antihistamines at usual or
increased doses are presently recommended as ﬁrst-line therapy
for patients with acute and chronic spontaneous urticaria and
angioedema. Alternative treatments include H2-antagonists,
corticosteroids, leukotriene receptor antagonists, other anti-
inﬂammatory drugs, immunosuppressants, omalizumab, and
intravenous immunoglobulins.
About one third of patients with CU will continue to
experience symptoms after 5 years of follow-up. Conse-
quently, it is important to provide early treatment to improve
patient’s quality of life. Reduction of the exposure to
precipitating and aggravating factors is also important, espe-
cially in patients with physical urticarias.
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